If the cells you would like to access are currently listed as unavailable
or you are ordering from outside of Europe please get in touch via
Contact@EBiSC.org.
CHDIi022-A
#22c1, CHDI-90002170
iPSC line
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
hPSCreg name | CHDIi022-A |
Alternative name(s) |
#22c1, CHDI-90002170
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
|
Provider |
|
Depositor | CHDI Foundation Inc. (CHDI) |
Distributors |
EBiSC
|
External Databases |
|
hPSCreg | CHDIi022-A |
BioSamples | SAMEA4675651 |
Cellosaurus | CVCL_VC93 |
Wikidata | Q54811788 |
General Information |
|
Publications | View all related publications on hPSCreg (1) |
This EBiSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Donor Information#
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 35-39 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA4675652 |
hIPSC Derivation#
General |
|
Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Age of donor (at collection) | 35-39 |
Passage number reprogrammed | P7 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
RT-PCR
|
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Selection criteria for clones | Clone morphology |
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 21 % |
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SSEA-4 |
Yes |
|||||
TRA 1-60 |
Yes |
|||||
SSEA-1 |
No |
|||||
POU5F1 (OCT-4) |
Yes |
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Sterility |
|
Inoculation for microbiological growth | No Contaminants Detected |
Mycoplasma | Not Detected |
Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |